Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
This is a randomized controlled trial to compare three currently available management strategies for women with a persisting pregnancy of unknown location (PPUL), which makes them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by methotrexate (MTX) for some (those that have evidence of a non visualized ectopic pregnancy) 2) Empiric treatment with MTX for all 3) Expectant management. Randomization will be 1:1:1 into these three arms. After randomization, they will be followed and treated clinically as is indicated by the progression of their condition. Primary outcome measures: uneventful decline of hCG to 5 IU/mL.
Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment
Persistent Pregnancy of Unknown Location Ectopic Pregnancy Methotrexate
You can join if…
Open to females ages 18 years and up
- Female with a persisting pregnancy of unknown location:
- A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization.
- Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days),showing < 15% rise per day, or < 50% fall between the first and last value.
- Patient is hemodynamically stable, hemoglobin>10 mg/dL
- Greater than or 18 years of age
You CAN'T join if...
- Hemodynamically unstable in need of acute treatment
- Most recent hCG> 5000 mIU/mL
- Patient obtaining care in relation to a recently completed pregnancy (delivery,spontaneous or elective abortion)
- Diagnosis of gestational trophoblastic disease
- Subject unwilling or unable to comply with study procedures
- Known hypersensitivity to MTX
- Presence of clinical contraindications for treatment with MTX
- Prior medical or surgical management of this gestation
- Subject unwilling to accept a blood transfusion
- University of California San Francisco accepting new patients
San Francisco, California, 94115, United States
- University of Utah not yet accepting patients
Salt Lake City, Utah, 84132, United States
- University of Oklahoma accepting new patients
Oklahoma City, Oklahoma, 73104, United States
- Washington University accepting new patients
Saint Louis, Missouri, 63108, United States
- University Of Illinois at Chicago accepting new patients
Chicago, Illinois, 60612, United States
- Northwestern University accepting new patients
Chicago, Illinois, 60611, United States
- Wayne State University accepting new patients
Southfield, Michigan, 48034, United States
- Greenville Health System accepting new patients
Greenville, South Carolina, 29605, United States
- Augusta University accepting new patients
Augusta, Georgia, 30912, United States
- Carolinas Medical Center - Women's Institute accepting new patients
Charlotte, North Carolina, 28204, United States
- University of North Carolina accepting new patients
Chapel Hill, North Carolina, 27599, United States
- University of South Florida accepting new patients
Tampa, Florida, 33606, United States
- University of Rochester accepting new patients
Rochester, New York, 14642, United States
- Pennsylvania State University accepting new patients
Hershey, Pennsylvania, 17033, United States
- University of Pennsylvania accepting new patients
Philadelphia, Pennsylvania, 19104, United States
- accepting new patients
- Start Date
- Completion Date
- Yale University
- Phase 3
- Study Type
- Last Updated
- May 1, 2017
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02152696.